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Biphosphonate (BPN) are widely used in clinics to treat meta-
static cancer and osteoporosis thus representing a problem not 
only for patients but also for workers involved in their prepara-
tion and administration. A similar exposure occurred years ago 
in match-making workers undergoing bone alterations similar 
to those consequent to BPN exposure. Osteonecrosis of the jaw 
(ONJ) is a main adverse effect related to BPN administration, 
which is performed in millions of patients worldwide for osteopo-
rosis and cancer therapy, thus representing an emerging problem 
in public health. In susceptible patients, BPN induce severe, pro-
gressive, and irreversible degeneration of facial bones, resulting 
in avascular ONJ often triggered by dental surgery. BPN induced 
ONJ occurs in subjects depending on lifestyle factors of both 
environmental and endogenous origins. Exogenous risk factors 
include cigarette smoke, alcohol consumption, bacterial infec-
tions, and cyclosporine therapy. Endogenous risk factors include 
systemic diseases such as diabetes or hypertension and adverse 
polymorphisms of genes involved in metabolism (CYPs, MTHFR), 
thrombosis (Factor V, Prothrombin), and detoxification (MDR).
Available molecular findings provide evidence that ONJ is related 
to risk-factors associated with environmental mutagenesis and 
gene-environment interactions. This issues may be useful to iden-
tify susceptible subjects by molecular analyses in order to prevent 
ONJ occurrence.
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Summary
Introduction
Biphosphonate (BPN) are widely used in clinics to treat 
metastatic cancer and osteoporosis thus representing a 
problem not only for patients but also for workers in-
volved in their preparation and administration. A similar 
exposure occurred years ago in match-making workers 
undergoing bone alterations similar to those consequent 
to BPN exposure. Osteonecrosis of the jaw (ONJ) is 
a main adverse effect related to BPN administration, 
which is performed in millions of patients worldwide for 
osteoporosis and cancer therapy [1].
In susceptible patients, BPN induce severe, progressive, 
and irreversible degeneration of facial bones, resulting 
in avascular ONJ triggered by dental surgery. BPN in-
duced ONJ occurs in subjects undergoing exposure to 
DNA-damaging agents as resulting from chemo and 
radiotherapy of neoplastic diseases or lifestyle factors. 
Thus, multiple risk factors of both environmental and 
endogenous origin contribute to BPN-related ONJ.
BPNs association with ONJ was first described in pa-
tients with cancer such as multiple myeloma, breast 
cancer, and prostate cancer treated with intravenous 
BPN  [2]. Nowadays BPN treatment is considered the 
main risk factor for the development of ONJ. This dis-
ease mainly appears in patients receiving intravenous 
BPNs for the treatment of cancer or oral BPNs for the 
treatment of osteoporosis [1]. Numerous risk factors of 
ONJ have been described mainly dealing with the in-
teraction between genetic and environmental factors. 
Gene–environment interactions underline how genetic 
and environmental factors jointly influence the risk of 
developing a disease. Recent studies shed light on a sub-
stantial genetic component in the etiology of dentistry 
disease, paralleled by the established effect of environ-
mental factors such as smoking, alcohol, radiation, and 
drugs [3].
The purpose of this review is to analyze how environ-
mental factors interact with genetic assets to contribute 
to the development of ONJ. This knowledge may be 
useful to identify individuals at risk for developing this 
pathology.
Exogenous risk factors and oral 
osteonecrosis
Biphosphonates and Osteonecrosis of the jaw
The structure of bisphosphonates (BPNs) is similar to 
that of endogenous pyrophosphate, a natural potent in-
hibitor of osteoclast-mediated bone resorption [4]. Con-
sequently, BPNs have the same properties of inorganic 
pyrophosphates, but are resistant to hydrolysis, as well 
as pyrophosphatase enzymes. Etidronate, precursor of 
pamidronate, is the base molecule of the more potent 
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second-generation drugs. The third generation structure 
of BPN was generated by the addition of amethyl group 
to the N-alcylic chain [5] (Tab. I).
The principal mechanism of BPN action in vivo is the in-
teraction with the mineralized component of bone tissue, 
preventing bone reabsorption via inhibition of osteoclast 
precursors [2].
BPNs can be classified into 2 groups based on the struc-
ture of R2 side chains. Nitrogen containing BPNs (eg, 
alendronic acid, risedronic acid, zoledronic acid) are 
much more potent with regard to their bone antiresorp-
tive activity than the non nitrogen-containing BPNs (eg, 
etidronic acid). Among the nitrogen containing BPNs, 
those with a tertiary nitrogen in a ring structure (hetro-
cyclic N-BPs; eg, risedronic acid and zoledronic acid) 
have the highest potency,  [6], inhibit the mevalonate 
pathway (i.e, the cholesterol synthesis pathway) and in-
duce caspase activity  [7] and are the strongest inhibi-
tors of farnesyl pyrophosphate synthase, which is a key 
branch-point enzyme in the mevalonate pathway  [8], 
partially explaining their anticancer effect. Zoledronic 
acid is the BP most extensively evaluated in vitro for its 
antitumor activity, including its effect on colon cancer 
cells. Osteonecrosis of the jaw has been reported among 
long term users of intravenous BPNs.
BPNs are hydrophilic molecules thereby not passing di-
rectly through biological membranes. Evidence suggests 
that BPNs are held in bone for several years even after 
the drug therapy is discontinued [9]. BPNs bind tightly 
to hydroxyapatite crystals situated in bone surfaces and 
there remain for long time, since they are not susceptible 
to enzymatic degradation by osseous pyrophosphatase. 
BPNs are constantly and gradually released from bone 
tissue into haematic circulation, entering in osteoclasts 
by endocytosis [10].
However, the etiopathogenic mechanisms of this patho-
logical condition are poorly understood. Although, sev-
eral pathways have been proposed for Bisphosphonate-
Related Osteonecrosis of the Jaw (BRONJ) occurrence, 
no single model can explain all morphological changes 
observed at the macro- and microscopic level. A recent 
research suggests that BPNs may promote an anti-an-
giogenic effect which contributes directly to the clinical 
features associated with BRONJ. Remarkably, the anti-
angiogenic effect promoting BRONJ might be in keep-
ing with the anti-neoplastic action of BPNs [11].
Recent studies revealed that BPNs induce osteoclast 
apoptosis by the farnesyl-diphosphate (FPP) synthase 
inhibition in the mevalonate pathway and subsequent 
accumulation of isopentenyl pyrophosphate [12]. BPNs 
inhibit osteoclast-mediated bone resorption and, conse-
quently, the suppressive effect of BPNs on bone tissue 
renewal debilitate the bone by inhibiting the removal of 
damaged cells from normal bone and increasing bone 
mineralization [13]. This phenomenon, which recogniz-
es the jawbone as target tissue, leads to ONJ with BPNs 
accumulation in skeletal sites for high bone turnover 
(Fig.  1). About 80% of ONJ cases reported heavy le-
sions, and 69% of cases occured after alveolar surgery, 
such as tooth extraction. Painful symptoms are reduced 
during chronic phases of the pathology and granulation 
tissue appears to delimit inflammation areas. The pos-
sible formation of fistulous tissue allows spontaneous 
draining of the purulent exudate, reducing the edema by 
defining the osteonecrotic area (Fig. 1). ONJ is often as-
ymptomatic for some time before clinical manifestation. 
As long as the overlying mucosa is intact and infection is 
not introduced into the bone, which has limited healing 
potential, there may be no clinical signs or symptoms of 
the underlying bone pathology [14].
The epidemiological relevance of ONJ
Osteoporosis is an age-related disease that causes dis-
ability, deterioration in the quality of life, and high costs 
in terms of public health  [15]. BPNs are used in the 
treatment of osteoporosis, and are taken by 73% of os-
teoporotic patients. Almost 190 million prescriptions of 
oral BPNs are dispensed worldwide each year [16]. The 
type of BPN used may play a role in the development of 
ONJ. This complication has been described after expo-
sure to the nitrogen-containing BPNs pamidronate and 
zoledronic acid. Zoledronic acid presents a higher risk 
than pamidronate [17]. Probably because of the higher 
inhibitory effect of zoledronic acid on bone turnover 
compared with pamidronate. Furthermore, zoledronic 
acid causes greater reduction in collagen type-I degra-
dation products (N-telopeptide) than pamidronate [18], 
confirming its greater antiresorptive activity. Wessel 
et al. indicate that zoledronate independently increases 
the risk of adverse effects; in fact, individuals undergo-
ing zoledronate therapy exhibit a 30-fold increased risk 
of developing ONJ  [19]. Despite, a recent study  [20] 
shows that intravenous BPN therapy for osteoporosis 
Tab. I. Biphosphonates approved for clinical use by United States of America Food and drugs Administration (FdA). N-Bps = Nitrogen-contain-
ing Biphosphonates.
Drug compound N-BPNs Medical uses Administration route
Alendronate yes Osteoporosis, paget’s disease Oral
Clodronate No hypercalcemia of malignancy Iv/Oral
etidronate No paget’s disease, hypercalcemia of malignancy, osteoporosis Oral
Ibandronate yes Osteoporosis, paget’s disease Oral/Iv
pamidronate yes hypercalcemia of malignancy, paget’s disease, osteoporosis Iv
risedronate yes Osteoporosis, paget’s disease Oral
Tiludronate No paget’s disease Oral
Zoledronate yes hypercalcemia of malignancy Iv
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does not measurably increase the risk of ONJ among 
postmenopausal women. Among cancer patients receiv-
ing high-dose intravenous BPNs, it was estimated an 
ONJ incidence of 1-12% [21]. Cartson et al. found that 
patients with conditions requiring intravenous BPNs had 
a much higher risk of developing adverse conditions in 
the jaw compared with patients taking oral BPNs [22]. 
In fact at least 50% of intravenous BPNs is bio-available 
for incorporation into the bone matrix compared with 
an average of 1% of oral BPNs absorbed by the gastro-
intestinal tract [23]. Approximately 94% of all osteone-
crosis cases are due to intravenous BPNs used and 6% 
are linked to oral BPNs [24, 25]. Among 368 cases of 
ONJ, 15 (4.1%) occurred in patients receiving BPNs to 
treat osteoporosis, considerably less than the 337 cases 
(91.6%) observed in patients receiving BPN to treat 
multiple myeloma, breast cancer, or prostate cancer. 
This difference is attributable to the different route of 
administration and dose used in these clinical situations, 
i.e., high dose parenteral administration in the context of 
cancer and low dose oral administration in the case of 
osteoporosis [25].
Lower ONJ incidence levels have been reported in those 
countries demonstrating a high level of health and oral 
hygiene (UK, Sweden)  [26], suggesting an important 
role for bacterial infection as a contributing risk factor. 
Moreover, bacterial flora could produce septic condi-
tions, involving bacteria such as Staphilococcus au-
reus and Pseudomonas aeruginosa. It remains unclear 
whether infection plays a primary causative role or is 
secondary to the appearance of the lesion, and whether it 
initially arises in the bone or soft tissue [27].
Currently available published incidence data for BRONJ 
are based on retrospective studies and estimates of cumu-
lative incidence range from 0.8 to 12% and 60-70% of 
cases are preceded by a dental surgical procedure [28]. 
A summary of ONJ risk factors related on BPNs is re-
ported in Table II.
Fig. 1. Osteonecrosis of the jaw as induced by BpNs in an eden-
tulous patient. Is reported an example of 80-year-old woman 
diagnosed with multiple myeloma was on long-term treatment 
with biphosphonates before developing ONJ in relation with den-
tal extractions. (A) Sagittal view of the patient’s profile. (B) mac-
roscopic appearance of oral osteonecrosis of the jaw. It can be 
seen that: 1) granulation tissue delimiting inflammation areas; 2) 
purulent exudate; 3) exposed osteonecrotic areas. (C) Bone loss 
in jaw is evident in particular in the lower right part of the Figure 
(panoramic x-ray).
Tab. II. risk factors identifying BpN-treated patients at high risk for developing ONJ following dental surgery.
Risk factor Rank Conferred risk References











Cause of BpN therapy Cancer > osteoporosis medium [20, 21]
BpN treatment cycles 18 cycles or more > 12 cycles or less high [62]
Oral hygiene poor > high medium [26]
Cyclosporine therapy yes > no Low [41]
Antiangiogenic therapies (e.g.interferon, 
etc.)
yes < no Low [45]
Smoking yes < no medium [46]
multiple myeloma yes < no high [27]
Systemic blood diseases and lymphomas yes < no medium [27]
Autoimmune diseases yes > no Low [46]
Local radiotherapy yes > no high [3]
Local dental and periodontal diseases yes > no medium [27, 49]
Obesity yes > no Low [19]
Cyp2C8 gene polymorphism TT homozygosity > heterozigosity and wild type high [51] 
prothrombin gene polymorphisms g20210 > A Low [53]
Leiden v factor gene polymorphisms Arg5406 > gln Low [53]
plasminogen-activating inhibitor-1 gene 
polymorphism
4g/4g homozygosity > heterozigosity and wild type Low [55]
multidrug resistance gene 1 
polymorphism
exon 26: C3435 > T;
exon 21: g2677 > T/A 
Low [56]
TNF-alpha gene polymorphism g307 > A Low [58]
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The role of dental procedures  
in the development of ONJ
Dental trauma, such as dental extraction, is the most 
common risk factor for ONJ, although cases have oc-
curred spontaneously [29]. In fact, while dental extrac-
tion greatly increases the need for repair of alveolar 
bone, the anti-resorptive function of BPNs may reduce 
the ability to perform this repair, thus causing ONJ. 
Disruption of blood flow could be another contributing 
factor [30]. Badros et al. [31] reported a significant as-
sociation between the occurrence of ONJ in dental ex-
traction (p = 0.009) and age (OR = 1.09; p = 0.003) in 
patients with multiple myeloma receiving intravenous 
BPN treatment.
Implant therapy is not allowed, in patients who under-
went intravenous BPNs. In contrast, surgery is usually 
not contraindicated with use of oral BPNs, but the pa-
tient should be informed of potential complication [32].
The jaw is highly susceptible to osteonecrosis because 
it is characterized by greater cellular turnover than the 
maxilla and other bones. Furthermore, the jaw has a ter-
minal circulation, hampering the establishment of ad-
ditional circulation during ischemic episodes. Ruggiero 
et al. highlighted ONJ prevalence in the jaw, its possible 
development from even simple surgical treatments, as 
well as it has s a vascular nature and predisposing septic 
parameters. In parallel, chewing causes constant trauma 
to the jaw, and exacerbates the instability of localized 
microfractures, [33].
Occupational risk
In vivo studies show that BPNs have toxic and genotoxic 
power [34], and therefore should be considered as “dan-
gerous drugs” during the preparation and handling. Ac-
cording to Polovich  [35] “hazardous drugs” represents 
a potential health risk to health care workers who may 
be exposed during preparation or administration. These 
drugs require special handling because of their inherent 
toxicities. Drugs that meet one or more of the following 
criteria should be handled as hazardous [36].
•	 Carcinogenicity
•	 Teratogenicity or developmental toxicity
•	 Reproductive toxicity
•	 Organ toxicity at low doses
•	 Genotoxicity
Structure or toxicity similar to drugs classified as haz-
ardous using the above criteria.
Some of these features are typical of BPNs and therefore 
during the preparation and administration of these drugs 
should be taken preventive safety measures. Preventive 
measures such as: the use of disposable gowns, gloves, 
masks, shoe covers, and the use of vertical laminar flow 
hoods to maintain the sterility of the product and the pro-
tection of the work surface of the operator. The work 
surface must be free of materials, with the exception 
of BPN drugs and must be cleaned with 70% alcohol 
and moist paper (guidelines ASHP) [36]. Therefore, the 
workers handling the BPNs must undergo health sur-
veillance pursuant to Legislative Decree 81/2008 on the 
same basis in workers exposed to processing and han-
dling of other dangerous drugs.
Environmental mutagens  
and oral osteonecrosis
Bisphosphonates and DNA damage
BPNs realize their antiosteoclast effects through modi-
fication of the Rho family GTPases, which include Rac 
GTPases [37]. Deletion of Rac1 gene results in a reduc-
tion of osteoclast formation because of its effects on pre-
osteoclast chemotaxis, actin assembly, and RANKL-
mediated reactive oxygen-species generation. Rac1 
deletion in knock-out mice increased trabecular-bone 
volume and trabecular number as compared with wild-
type and Rac2-null mice [38].
Two aromatic bis-(2-chloroethyl) amino-bisphosphonic 
acids were investigated for their genotoxic potential as 
determined in S. typhimurium and mammalian cells in 
vitro. Both compounds induced a two-fold increase in 
his+ revertants in S. typhimurium TA1535 following 
metabolic activation with subcellular liver fractions, 
thus demonstrating the mutagenic attitude of BPNs. In 
vivo toxicity and genotoxicity parameters were deter-
mined in liver and bone marrow cells after treatment. 
The genotoxicity of both compounds was exerted in sev-
eral tissues but was lower in bone marrow cells than in 
liver cells [34].
BPNs induce apoptosis in osteoclasts but prevent apop-
tosis in osteoblasts. Both effects are related to BPNs 
binding to connexin 43. The prevention of osteoblastic 
apoptosis is mediated by Cx43 hemi channel opening 
and related activation of the extracellular signal-regulat-
ed kinases). However, Cx43, is also involved in BPNs 
pro-apoptotic effects in osteoclast [39].
Exogenous risk factors for oral 
osteonecrosis other than BPNs: drugs, 
smoke, and ionizing radiation
Exogenous risk factors for ONJ include cigarette smoke, 
alcohol consumption, bacterial infections, and cyclospo-
rine therapy. Endogenous risk factors include systemic 
diseases such as diabetes or hypertension and adverse 
polymorphisms of genes involved in metabolism such 
as CYPs, MTHFR.
Available molecular findings provide evidence that ONJ 
recognizes risk-factors associated with environmental 
mutagenesis and gene-environment interactions.
Glucocorticoid administration is a risk factor for osteo-
necrosis [40]. Calcineurin-inhibitors, particularly cyclo-
sporine, may increase the risk of osteonecrosis because 
of vasoconstricting effects [41]. Cyclosporine is a cyclic 
hydrophobic endecapeptide derived from the metabolic 
products of two species of fungi, Trichoderma polys-
porum and Cylindrocarpon lucidum. The antimicrobial 
activity of cyclosporine is weak but this compound has 
a remarkable inhibitory effect on lymphocyte prolifera-
tion  [42]. Cyclosporine inhibits many of the processes 
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involved in T-cell-mediated immune responses; in par-
ticular, a concentration of 10/20 ng/ml inhibits the syn-
thesis of interleukin-2, limiting the amplification of cy-
totoxic T lymphocytes. Cyclosporine has a selective ac-
tivity against T lymphocytes: T suppressor lymphocytes 
remain unaffected, while cytotoxic T lymphocytes and 
T helper cells are susceptible to drug. Cyclosporine is 
a widely used immunosuppressive agent, predominantly 
for transplant patients. It is well recognized that trans-
plant patients are prone to developing squamous carci-
noma of the skin and mucosa. Cyclosporine is a specific 
ligand for calcineurin, a ubiquitously expressed cellu-
lar serine/threonine phosphatase that plays important 
roles in the immune system and cardiac muscle. Many 
genes were identified to be responsive to cyclosporine 
treatment, including regulatory molecules involved in 
apoptosis, DNA damage repair, and cell-cycle regula-
tion [43]. The mechanisms involved in the pathogenesis 
of cyclosporin A-induced gingival hyperplasia are not 
well understood. In mice treated intraperitoneally with 
increasing doses of cyclosporine A, oral mucosa has in-
creased vascularity, thickening of the epithelial tissue 
and connective tissue, edema, mononuclear infiltrate 
and gingival hyperplasia [44]. Anti angiogenetic agents 
induce a risk of ONJ when administered concurrently 
with BPNs [45]. This situation frequently occurs in pa-
tient undergoing long-term treatment with interferon for 
chronic viral hepatitis or for anti-cancer therapies.
Cigarette smoke is an extremely complex mixture of mu-
tagens representing a risk factor for a variety of inflam-
matory, neoplastic, and vascular diseases. The direct ef-
fect of smoke on blood vessel significantly contribute to 
ONJ. In fact, smoke causes increased vasoconstriction 
and thrombosis in the bone, leading to ischemic states 
that may underlie the pathophysiology of osteonecro-
sis  [46]. It has been demonstrated that smoke increase 
mtDNA deletetion (common deletion 4977) in artery 
and inhibits the activator of plasminogen inhibitor 1 in-
creasing the thrombosis risk [47].
In addition, ionizing radiation constitute a risk factor for 
ONJ [3]. In fact, 93% of patients with ONJ was previ-
ously treated with a radiotherapy regimen with doses of 
over 6,500 cGy. This leads to a adverse effects exerted 
by ionizing radiation towards bone tissue including clas-
togenic DNA damage, oxidative stress, stem cell deple-
tion [3] (Tab. II).
ONJ biomarkers
The decreased serum levels of telopeptide type I col-
lagen is a biological marker in ONJ. To validate this 
hypothesis, Bagan et  al. compared 15 patients with 
bisphosphonate-induced ONJ to a control group of 10 
healthy age- and gender-matched individuals [48]. Their 
preliminary results showed decreased telopeptide of 
type I collagen serum levels in patients with ONJ, but 
further studies containing a greater number of patients 
are needed to prove the utility of this finding as a bio-
logical and prognostic marker in ONJ [48].
Endogenous risk factors and oral 
osteonecrosis
Systemic and local risk factors
ONJ may be associated with a number of different pre-
disposing systemic conditions such as haemoglobinopa-
thies, coagulopathies, lymphoproliferative disorders, 
Paget’s disease, phosphorous exposure, and local condi-
tions of sepsis (apical or periodontal), trauma (surgical 
or accidental) and radiotherapy. The exact role of these 
factors involved in the pathogenic process remains to be 
established [26]. Patients with multiple myeloma are at 
highest risk for ONJ, possibly due to inherent myeloma 
bone-metabolism abnormalities, such as increased activ-
ity of osteoclasts and inhibition of osteoblast function, 
leading to enhanced bone resorption.
Dental risk factors include periodontal disease, dental 
abscesses, surgical procedures involving the bone, and 
trauma from ill-fitting dentures, all of which may lead 
to mucosal lesions [26]. Oral conditions that predispose 
to tooth extraction, such as advanced caries, moderate to 
advanced periodontitis, and xerostomia, are indirect risk 
factors for ONJ [49]. The association of ONJ with poor 
dental health is established [50].
Obesity was also found to be associated with ONJ risk 
in cancer patients. Although it is currently unclear which 
pathway might cause an obese person to develop ONJ. 
In fact, obesity is potentially correlated with an increase 
in masticatory function that could lead to oral-bone mi-
crotraumas [19].
Gene polymorphisms
Like other degenerative diseases, ONJ is caused by a 
combination of environmental and genetic risk factors. 
The potential role of genetics in the development of ONJ 
has been explored in multiple myeloma patients under-
going BPN therapy. Four single nucleotide polymor-
phisms (SNPs) were considered (rs1934951, rs1934980, 
rs1341162, and rs17110453) mapped within the cyto-
chrome P450-2C gene (CYP2C8). The analysis of SNP 
rs1934951 and 3 additional SNPs allocated on the same 
gene (i.e. rs1934980, rs1341162, and rs17110453) high-
lights an over-representation of the homozygous TT 
genotype in cases as compared with controls. Thus, 
individuals homozygous for the TT genotype have an 
increased risk of developing ONJ (OR  =  12.75)  [51]. 
CYP2C8 gene polymorphisms can affect several biolog-
ic pathways [52], which could be involved in the devel-
opment of ONJ in patients treated with BPNs. Because 
ONJ is an avascular necrosis of the jawbone, the altera-
tion of this pathway due to a variant of CYP2C8 could 
make development of osteonecrosis. These results sug-
gest that the rs1934951 polymorphism on CYP2C8 gene 
is a risk factor for ONJ. This information could help us 
to exclude patients at high risk from BPN therapy, and 
to take specific preventive measures.
Another study examined the association between osteo-
necrosis and thrombotic polymorphisms in genes encod-
ing factor V Leiden and the prothrombin (20210A) gene 
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mutation. Factor V Leiden and the prothrombin 20210A 
gene mutations occurred significantly (p  =  0.006) fre-
quently in patients with osteonecrosis than in a popula-
tion of 282 healthy volunteers (OR = 3.1, 95% CI = 1.4–
6.6). This study suggests that coagulation abnormalities 
in the form of factor V Leiden and prothrombin 20210A 
gene mutations might play a role in osteonecrosis [53].
Major thrombophilic mutations have been identified 
as risk factors for non-traumatic osteonecrosis in Cau-
casians. The factor V Leiden mutation was present in 
18% of the patients compared with 4.6% of the control 
subjects, resulting in a statistically significant difference 
(OR = 4.5). Factor V Leiden polymorphism is also as-
sociated with osteonecrosis of the femoral head  [54]. 
Genetic studies in subgroups of patients with steroid-
induced osteonecrosis focused on coagulation, fibrino-
lytic factors and homocysteine metabolism. A positive 
association of plasminogen-activating inhibitor-1 (PAI), 
MTHFR and factor V Leiden polymorphisms with ste-
roid-induced ON was reported [55].
High plasma PAI-1 concentrations were associated with 
coronary artery disease and other thrombotic disorders. 
Regarding the effect of PAI-1 polymorphism on osteo-
necrosis, it has been reported that 4G/4G PAI-1 homo-
zygosis is a risk factor for osteonecrosis [56]. It has been 
demonstrated that cigarette smoke is a potent induced of 
PAI-1 gene expression [47] thus providing evidence for 
the interaction between smoking and an adverse genetic 
PAI-1 polymorphism as contributing to thrombosis and 
ONJ.
Polymorphisms in the multidrug resistance gene 1 
(ABCB1), which encodes the drug-transport protein, P-
glycoprotein leads to drug resistance to various agents, 
including steroids. It was found that the 3435TT exon 
1 genotype had a protective effect against the develop-
ment of ONJ. The same result was also observed with 
homozygosity in the mutant 2677T/A variants. As ONJ 
is a rare occurrence, systematic pharmacogenetic stud-
ies are needed to assess the possibility of genetic sus-
ceptibility  [57]. The TNF cytokine is crucial to both 
immune and inflammatory responses. TNF up-regulates 
host defense mechanisms and also affects tissue physiol-
ogy, including bone resorption, which is a crucial step 
in ONJ. Over-expression of TNF in the periodontium 
may be harmful to the host. Normally, TNF and other 
pro-inflammatory agents are regulated by IL-10, sug-
gesting that some deficiency in this regulation mecha-
nism may be linked to the disease. Although several 
polymorphisms have been reported in the TNF-A pro-
moter, the majority of studies have been focused on the 
G/A polymorphism at position-307 because most of the 
other polymorphisms being functionally silent. TNF 
adverse polymorphism increase the risk of periodontal 
bone loss [58] and periodontitis [59]. Main genetic poly-
morphisms representing risk factors for ONJ are listed 
in Table II.
Conclusions
Risk factors of both exogenous and endogenous ori-
gin play an important pathogenic role in the develop-
ment of ONJ. It is important to identify patients at high 
risk for developing ONJ after dental surgery. This ap-
proach should be useful to (a) identify those patients in 
which dental surgery could cause a risk rather than a 
benefit; (b) apply preventive intervention before den-
tal surgery to decrease ONJ risk; (c) define time and 
type (less or more invasive) of surgical intervention. 
The American Dental Association has produced guide-
lines regarding the dental management of patients pre-
scribed BPNs [60]. A recognized therapeutic protocol 
that allows for clear identification of BNP-related ONJ 
does not currently exist. Common guidelines present 
in the literature consist of a first approach to acute 
phases with broad antibiotic therapy and antimicrobial 
rinses such as 0.12% chlorhexidine, and, for second in-
cidences, substitution with a specific therapy after the 
antibiogram.
Since the half-life of BPNs in human bone can reach 
more than 10 years [61] it has been generally questioned 
whether the interruption of BPNs will be of any ben-
efit [62, 63]. Migliorati et al. suggest that, until prospec-
tive studies of BPN-related ONJ provide information 
about effective treatment protocols, the best approach is 
prevention, with the dental practitioner and the physician 
working collaboratively [64]. Translation of basic scien-
tific findings into clinical practice is the essential prem-
ise for the development of future preventive strategies. 
Risk for ONJ appearance is greatly influenced by geno-
toxic factors related to oxidative damage such as those 
related to bacterial infections, inflammation, smoking, 
and ionizing radiation. Administration of chemopreven-
tive drugs is a possible strategy to overcome this mecha-
nisms in high risk patients, such an approach being usu-
ally referred as targeted chemoprevention [65, 66]. Fur-
thermore BPN being mutagenic and genotoxic represent 
an occupational risk for workers involved in their pro-
duction and administration thus have to be considered 
“hazardous drugs”.
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